Moderna

Moderna announced a three-year business strategy targeting up to 10% revenue growth in 2026 while building a large seasonal vaccine franchise for at-risk populations.

Pfizer's mRNA-based influenza vaccine demonstrated 34.5% greater effectiveness against influenza A compared to standard flu vaccines in a Phase 3 trial involving over 18,000 participants aged 18-64.

Moderna is investing over $140 million to bring drug product manufacturing capabilities to its Norwood, Massachusetts facility, completing full end-to-end domestic mRNA production.

BIOVECTRA, part of Agilent Technologies, has partnered with Revolution Biomanufacturing to provide integrated mRNA sequence design and GMP manufacturing services.

Moderna has dosed the first patient with mRNA-2808, an investigational mRNA-based T-cell engager therapy for relapsed or refractory multiple myeloma, marking the company's first T-cell engager to reach clinical testing.

Moderna stock jumped as much as 12% following reports that the company is in discussions with at least one large pharmaceutical company about a potential deal of significant scope.

4basebio PLC announces that a global Tier 1 pharmaceutical partner has begun dosing patients with an mRNA therapy developed using the company's proprietary opDNA® template following FDA IND approval.

Moderna's mRNA-1345 RSV vaccine demonstrated safety and efficacy in a Phase III trial of 150 solid organ transplant recipients, with adverse events being mostly grade 1-2 and resolving within 2-3 days.

Moderna's Phase 3 trial of mRNA-1647, an investigational cytomegalovirus vaccine, failed to meet its primary efficacy endpoint of preventing CMV infection in seronegative women aged 16-40.

Monash University researchers have uncovered the genetic code governing how mutations affect RNA splicing, a critical cellular process for protein production.